Kiniksa Pharmaceuticals Ltd (KNSA)
17.62
-0.24
(-1.37%)
USD |
NASDAQ |
Apr 25, 16:00
17.62
0.00 (0.00%)
After-Hours: 20:00
Kiniksa Pharmaceuticals Research and Development Expense (Quarterly): 20.05M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 20.05M |
| September 30, 2023 | 17.11M |
| June 30, 2023 | 23.77M |
| March 31, 2023 | 15.17M |
| December 31, 2022 | 14.39M |
| September 30, 2022 | 16.48M |
| June 30, 2022 | 13.80M |
| March 31, 2022 | 20.82M |
| December 31, 2021 | 27.43M |
| September 30, 2021 | 19.24M |
| June 30, 2021 | 23.94M |
| March 31, 2021 | 28.68M |
| December 31, 2020 | 37.40M |
| September 30, 2020 | 31.42M |
| Date | Value |
|---|---|
| June 30, 2020 | 22.32M |
| March 31, 2020 | 20.90M |
| December 31, 2019 | 22.89M |
| September 30, 2019 | 22.01M |
| June 30, 2019 | 30.85M |
| March 31, 2019 | 59.25M |
| December 31, 2018 | 36.12M |
| September 30, 2018 | 20.64M |
| June 30, 2018 | 17.20M |
| March 31, 2018 | 12.63M |
| December 31, 2017 | 29.93M |
| September 30, 2017 | 14.01M |
| June 30, 2017 | 9.272M |
| March 31, 2017 | 3.145M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.80M
Minimum
Jun 2022
37.40M
Maximum
Dec 2020
22.56M
Average
22.01M
Median
Sep 2019
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 35.03M |
| Geron Corp | 32.91M |
| United Therapeutics Corp | 151.40M |
| Vanda Pharmaceuticals Inc | 24.34M |
| TG Therapeutics Inc | 14.60M |